Free Trial
→ They rigged the game (From Investors Alley) (Ad)
NASDAQ:BIVI

BioVie 5/12/2023 Earnings Report

BioVie logo
$0.82 -0.01 (-1.26%)
As of 04:00 PM Eastern
Earnings HistoryForecast

BioVie EPS Results

Actual EPS
-$0.43
Consensus EPS
-$0.31
Beat/Miss
Missed by -$0.12
One Year Ago EPS
N/A

BioVie Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

BioVie Announcement Details

Quarter
Date
5/12/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

BioVie's Q3 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled on Friday, May 9, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

BioVie Earnings Headlines

BIOVIE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioVie Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
April 30 at 9:00 PM | globenewswire.com
Head to Head Contrast: DiaMedica Therapeutics (NASDAQ:DMAC) versus BioVie (NASDAQ:BIVI)
April 22, 2025 | americanbankingnews.com
They rigged the game
The U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs China for growth. Nvidia depends on the global chip chain. The MAG 7 have already bled $3.4 trillion — and the next phase could be worse. But while panic sets in, there's a small group of investors pulling in reliable, high-yield monthly income…
April 30, 2025 | Investors Alley (Ad)
BioVie initiates SUNRISE-PD trial assessing Bezisterim
April 17, 2025 | markets.businessinsider.com
BioVie, Inc.: BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson's Disease with First Patient Enrolled
April 16, 2025 | finanznachrichten.de
BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson’s Disease with First Patient Enrolled
April 16, 2025 | markets.businessinsider.com
See More BioVie Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioVie? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioVie and other key companies, straight to your email.

About BioVie

BioVie (NASDAQ:BIVI), a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

View BioVie Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles